Brookstone Capital Management’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $227K | Sell |
2,506
-38
| -1% | -$3.18K | ﹤0.01% | 1209 |
|
|
2026
Q1 | $204K | Sell |
2,544
-371
| -13% | -$30.6K | ﹤0.01% | 1157 |
|
|
2025
Q4 | $248K | Sell |
2,915
-419
| -13% | -$34.4K | ﹤0.01% | 1048 |
|
|
2025
Q3 | $259K | Sell |
3,334
-2,181
| -40% | -$170K | ﹤0.01% | 1019 |
|
|
2025
Q2 | $431K | Sell |
5,515
-133
| -2% | -$9.92K | 0.01% | 785 |
|
|
2025
Q1 | $409K | Buy |
5,648
+164
| +3% | +$11.7K | 0.01% | 758 |
|
|
2024
Q4 | $406K | Buy |
5,484
+616
| +13% | +$43.1K | 0.01% | 749 |
|
|
2024
Q3 | $321K | Sell |
4,868
-2,414
| -33% | -$175K | ﹤0.01% | 818 |
|
|
2024
Q2 | $636K | Sell |
7,282
-4,993
| -41% | -$442K | 0.01% | 590 |
|
|
2024
Q1 | $1.17M | Buy |
12,275
+383
| +3% | +$32.2K | 0.02% | 452 |
|
|
2023
Q4 | $907K | Buy |
11,892
+892
| +8% | +$62.1K | 0.02% | 482 |
|
|
2023
Q3 | $760K | Sell |
11,000
-3,748
| -25% | -$301K | 0.02% | 486 |
|
|
2023
Q2 | $1.33M | Buy |
14,748
+6,668
| +83% | +$580K | 0.03% | 382 |
|
|
2023
Q1 | $679K | Buy |
8,080
+1,676
| +26% | +$132K | 0.01% | 528 |
|
|
2022
Q4 | $493K | Buy |
6,404
+269
| +4% | +$20.7K | 0.01% | 581 |
|
|
2022
Q3 | $507K | Buy |
6,135
+141
| +2% | +$13.6K | 0.01% | 561 |
|
|
2022
Q2 | $590K | Buy |
5,994
+223
| +4% | +$23.1K | 0.01% | 534 |
|
|
2022
Q1 | $701K | Buy |
+5,771
| New | +$647K | 0.01% | 482 |
|
|
2021
Q2 | – | Sell |
-6,729
| Closed | -$563K | – | 720 |
|
|
2021
Q1 | $563K | Buy |
6,729
+164
| +2% | +$13.9K | 0.02% | 338 |
|
|
2020
Q4 | $599K | Buy |
6,565
+115
| +2% | +$9.54K | 0.02% | 305 |
|
|
2020
Q3 | $515K | Sell |
6,450
-628
| -9% | -$49K | 0.02% | 269 |
|
|
2020
Q2 | $489K | Sell |
7,078
-692
| -9% | -$49.2K | 0.03% | 242 |
|
|
2020
Q1 | $489K | Sell |
7,770
-261
| -3% | -$18.8K | 0.03% | 213 |
|
|
2019
Q4 | $625K | Sell |
8,031
-324
| -4% | -$25.3K | 0.03% | 253 |
|
|
2019
Q3 | $612K | Sell |
8,355
-1,035
| -11% | -$72.7K | 0.03% | 238 |
|
|
2019
Q2 | $578K | Buy |
9,390
+1,014
| +12% | +$61.3K | 0.03% | 228 |
|
|
2019
Q1 | $534K | Buy |
8,376
+939
| +13% | +$53.6K | 0.03% | 202 |
|
|
2018
Q4 | $380K | Sell |
7,437
-378
| -5% | -$19.1K | 0.03% | 198 |
|
|
2018
Q3 | $454K | Buy |
7,815
+1,623
| +26% | +$79.4K | 0.03% | 287 |
|
|
2018
Q2 | $300K | Sell |
6,192
-1,566
| -20% | -$73.1K | 0.03% | 300 |
|
|
2018
Q1 | $361K | Buy |
+7,758
| New | +$337K | 0.03% | 251 |
|
|
2015
Q4 | – | Sell |
-222
| Closed | -$5K | – | 378 |
|
|
2015
Q3 | $5K | Hold |
222
| – | – | ﹤0.01% | 1398 |
|
|
2015
Q2 | $5K | Buy |
+222
| New | +$5.01K | ﹤0.01% | 1480 |
|
Other funds holding EW
Brookstone Capital Management's EW Position: Q2 2026 in Review
Brookstone Capital Management reduced its Edwards Lifesciences (EW) stake by 1.5% in Q2 2026, selling an estimated $3.18K and leaving 2,506 shares worth $227K. The position accounts for ﹤0.01% of the portfolio, ranked #1209.
Brookstone Capital Management first reported a position in EW in Q2 2015 and has held it in 33 quarters since. The position peaked at $1.33M in Q2 2023. 1,327 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- Brookstone Capital Management held 2,506 shares of Edwards Lifesciences worth $227K as of Q2 2026.
- Brookstone Capital Management sold 38 Edwards Lifesciences shares in Q2 2026, an estimated $3.18K.
- Edwards Lifesciences made up ﹤0.01% of Brookstone Capital Management's portfolio in Q2 2026, its #1209 holding.
- Brookstone Capital Management first reported a position in Edwards Lifesciences in Q2 2015 and has held it in 33 quarters since.
- Brookstone Capital Management's Edwards Lifesciences position peaked at $1.33M in Q2 2023.
- 1,327 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on Brookstone Capital Management's 13F filing for Q2 2026, filed 15 Jul 2026.